文献速递神经眼科眼底病与葡萄膜炎

Leber遗传性视神经病变基因治疗:全部患者组的不良事件与视力结果

Leber Hereditary Optic Neuropathy Gene Therapy: Adverse Events and Visual Acuity Results of All Patient Groups.
PubMed 文献 · Am J Ophthalmol · 2022-03-07

这项1期临床试验在G11778A Leber遗传性视神经病变(LHON)患者中评估单眼玻璃体内注射AAV2(Y444,500,730F)-P1ND4v2的安全性。28例患者分三组(慢性双侧视力丧失、急性双侧视力丧失、单侧视力丧失),中位随访24个月。载体相关不良事件仅为葡萄膜炎(8/28,29%),与载体剂量相关:高剂量以上组5/7(71%)vs 低、中、高剂量组3/21(14%)(P < .001)。作者认为安全性良好,疗效效应即使存在也可能很小且与剂量无关。

要点

  • 载体相关不良事件仅为葡萄膜炎(8/28,29%),未导致可归因的视力后遗症。
  • 葡萄膜炎与载体剂量相关:高剂量以上组5/7(71%)vs 低、中、高剂量组3/21(14%)(P < .001)。
  • 第3组所有研究眼(BCVA ≥20/40)在治疗第一年内丧失≥15个字母。

核心结论

  • G11778A LHON基因治疗具有良好的安全性。
  • 作者认为如果存在疗效效应,该效应可能很小且与剂量无关。
  • 证明疗效需要将患者随机分配到双眼均未接受载体治疗的对照组。

研究设计与样本

  • 1期临床试验,单中心设置。
  • 纳入G11778A LHON患者:第1组为慢性双侧视力丧失>12个月(n=11),第2组为急性双侧视力丧失<12个月(n=9),第3组为单侧视力丧失(n=8)。
  • 干预为单眼玻璃体内注射AAV2(Y444,500,730F)-P1ND4v2,第1组和第2组注射较差眼,第3组注射较好眼,剂量包括低、中、高和更高剂量。
  • 平均随访24个月(范围12-36个月);BCVA与已发表的前瞻性自然病史队列的指定替代研究眼和对侧眼进行比较。

主要发现

  • 发生葡萄膜炎8/28(29%),是唯一与载体相关的不良事件,未导致可归因的视力后遗症。
  • 葡萄膜炎与载体剂量相关:更高剂量眼5/7(71%)vs 低、中或高剂量眼3/21(14%)(P < .001)。
  • 需要治疗的葡萄膜炎与血清AAV2中和抗体滴度升高相关(p=0.007),但与血清AAV2聚合酶链反应无关。
  • 第1组和第2组的部分治疗眼和对侧眼、以及自然病史受试者的部分替代研究眼和对侧眼,出现BCVA改善≥15个字母。
  • 第3组所有研究眼(BCVA ≥20/40)在治疗第一年内丧失≥15个字母。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess safety of gene therapy in G11778A Leber hereditary optic neuropathy (LHON). DESIGN: Phase 1 clinical trial. METHODS: Setting: single institution. PARTICIPANTS: Patients with G11778A LHON and chronic bilateral visual loss >12 months (group 1, n = 11), acute bilateral visual loss <12 months (group 2, n = 9), or unilateral visual loss (group 3, n = 8). INTERVENTION: unilateral intravitreal AAV2(Y444,500,730F)-P1ND4v2 injection with low, medium, high, and higher doses to worse eye for groups 1 and 2 and better eye for group 3. OUTCOME MEASURES: Best-corrected visual acuity (BCVA), adverse events, and vector antibody responses. Mean follow-up was 24 months (range, 12-36 months); BCVAs were compared with a published prospective natural history cohort with designated surrogate study and fellow eyes. RESULTS: Incident uveitis (8 of 28, 29%), the only vector-related adverse event, resulted in no attributable vision sequelae and was related to vector dose: 5 of 7 (71%) higher-dose eyes vs 3 of 21 (14%) low-, medium-, or high-dose eyes (P < .001). Incident uveitis requiring treatment was associated with increased serum AAV2 neutralizing antibody titers (p=0.007) but not serum AAV2 polymerase chain reaction. Improvements of ≥15-letter BCVA occurred in some treated and fellow eyes of groups 1 and 2 and some surrogate study and fellow eyes of natural history subjects. All study eyes (BCVA ≥20/40) in group 3 lost ≥15 letters within the first year despite treatment. CONCLUSIONS: G11778A LHON gene therapy has a favorable safety profile. Our results suggest that if there is an efficacy effect, it is likely small and not dose related. Demonstration of efficacy requires randomization of patients to a group not receiving vector in either eye.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Lam BL, Feuer WJ, Davis JL, et al. Leber Hereditary Optic Neuropathy Gene Therapy: Adverse Events and Visual Acuity Results of All Patient Groups. Am J Ophthalmol. 2022. PMID: 35271811. doi:10.1016/j.ajo.2022.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。